First Affiliated Hospital of Anhui Medical University | China
Dr. Ran Wang is an accomplished respiratory medicine researcher whose work has significantly advanced the understanding of pulmonary hypertension and chronic obstructive pulmonary disease (COPD). With more than two decades of clinical and scientific experience, he has extensively investigated the molecular mechanisms underlying hypoxic pulmonary hypertension and COPD pathogenesis. His research has contributed to improved insights into vascular remodeling, inflammatory signaling, and pulmonary vascular resistance, helping to strengthen the scientific basis for future diagnostic and therapeutic strategies.
He has successfully led multiple high-impact research projects, including two funded by the National Natural Science Foundation and three additional provincial-level studies. His work spans basic, translational, and clinical domains, integrating experimental models with patient-centered research to address key challenges in pulmonary vascular diseases. He has authored or co-authored 59 peer-reviewed journal articles, including over 50 SCI-indexed publications and more than 20 as first or corresponding author. His research outputs include four patents related to respiratory disease mechanisms and clinical application innovations.
In addition to his scholarly publications, he serves on editorial boards of leading journals such as Journal of Cancer Research and Clinical Oncology, BMC Pulmonary Medicine, and Cancer Control, contributing to the advancement of scientific discourse in respiratory and cancer research.
Featured Publications:
-
Han, R., Guan, Y., Li, P., Tang, M., Fei, G., Zeng, D., & Wang, R. (2025). Real-world efficacy of oral azvudine in hospitalized patients with COVID-19: A multicenter retrospective cohort study. Journal of Infection and Public Health, 18(12), 102987.
-
Liu, Y., Wang, R., & Jiang, T. (2025). RNA-binding proteins as a molecular link between COPD and pulmonary hypertension. International Journal of Medical Sciences, 22(8), 1979–1991.
-
Rao, B., Wang, D., Yang, M., … et al. (2025). Real-world effectiveness and safety of oral Azvudine versus Paxlovid for COVID-19 in patients with kidney disease: A multicenter, retrospective, cohort study. BMC Infectious Diseases, 25, 275.